title: Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
authors.affiliation: Merck & Co., Inc., Whitehouse Station, New Jersey, USA. rajesh_krishna@merck.com
authors.forename: R
authors.initials: R
authors.lastname: Krishna
authors.forename: A J
authors.initials: AJ
authors.lastname: Bergman
authors.forename: B
authors.initials: B
authors.lastname: Jin
authors.forename: M
authors.initials: M
authors.lastname: Fallon
authors.forename: J
authors.initials: J
authors.lastname: Cote
authors.forename: P
authors.initials: P
authors.lastname: Van Hoydonck
authors.forename: T
authors.initials: T
authors.lastname: Laethem
authors.forename: I N
authors.initials: IN
authors.lastname: Gendrano
authors.forename: K
authors.initials: K
authors.lastname: Van Dyck
authors.forename: D
authors.initials: D
authors.lastname: Hilliard
authors.forename: O
authors.initials: O
authors.lastname: Laterza
authors.forename: K
authors.initials: K
authors.lastname: Snyder
authors.forename: C
authors.initials: C
authors.lastname: Chavez-Eng
authors.forename: R
authors.initials: R
authors.lastname: Lutz
authors.forename: J
authors.initials: J
authors.lastname: Chen
authors.forename: D M
authors.initials: DM
authors.lastname: Bloomfield
authors.forename: M
authors.initials: M
authors.lastname: De Smet
authors.forename: L M
authors.initials: LM
authors.lastname: Van Bortel
authors.forename: M
authors.initials: M
authors.lastname: Gutierrez
authors.forename: N
authors.initials: N
authors.lastname: Al-Huniti
authors.forename: K
authors.initials: K
authors.lastname: Dykstra
authors.forename: K M
authors.initials: KM
authors.lastname: Gottesdiener
authors.forename: J A
authors.initials: JA
authors.lastname: Wagner
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D053480:Cholesterol Ester Transfer Proteins / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology*; D012016:Reference Values; D012307:Risk Factors; D012680:Sensitivity and Specificity; D055815:Young Adult
chemical_list: D053480:Cholesterol Ester Transfer Proteins; D023303:Oxazolidinones; C530884:anacetrapib